SGMO
Sangamo Therapeutics, IncCompany with tickers: SGMO
CIK
1001233
CUSIP
800677106
Shares Outstanding
414,288,847
13F Activity (30d)
65 filings
63 filers
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Shares |
|---|---|---|---|---|
| 2021-03-11 | Fontenot Jason D. |
SVP, Chief Scientific Officer | Other | 0 |
| 2021-03-11 | Fontenot Jason D. |
SVP, Chief Scientific Officer | Other | 63,307 |
| 2021-03-11 | Fontenot Jason D. |
SVP, Chief Scientific Officer | Other | 0 |
| 2021-03-23 | LOEB GARY |
EVP, General Counsel & Sec. | Sell | 543 |
| 2021-03-23 | LOEB GARY |
EVP, General Counsel & Sec. | Convert | 11,981 |
| 2021-03-23 | LOEB GARY |
EVP, General Counsel & Sec. | Sell | 5,000 |
| 2021-03-23 | LOEB GARY |
EVP, General Counsel & Sec. | Convert | 11,981 |
| 2021-03-23 | LOEB GARY |
EVP, General Counsel & Sec. | Sell | 11,981 |
| 2021-03-25 | Duraibabu Prathyusha |
Director | Tax | 345 |
| 2021-04-25 | Fontenot Jason D. |
SVP, Chief Scientific Officer | Tax | 811 |
| 2021-04-25 | Duraibabu Prathyusha |
Director | Tax | 662 |
| 2021-06-11 | Duraibabu Prathyusha |
Director | Award | 15,000 |
| 2021-06-11 | Duraibabu Prathyusha |
Director | Award | 7,500 |
| 2021-06-25 | McClung David Mark |
EVP, Chief Operating Officer | Tax | 11,525 |
| 2021-08-02 | Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY | Other | 0 |
| 2021-08-02 | Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY | Other | 0 |
| 2021-08-02 | Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY | Other | 47,095 |
| 2021-08-13 | Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY | Award | 15,000 |
| 2021-08-13 | Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY | Award | 7,500 |
| 2021-10-29 | Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY | Tax | 140 |
| 2021-11-26 | BIOGEN INC. |
10% Owner | Sell | 28,884 |
| 2021-12-01 | BIOGEN INC. |
10% Owner | Sell | 730 |
| 2021-12-02 | BIOGEN INC. |
10% Owner | Sell | 1,874 |
| 2021-12-07 | BIOGEN INC. |
10% Owner | Sell | 52,178 |
| 2021-12-08 | BIOGEN INC. |
10% Owner | Sell | 75,814 |
| 2021-12-09 | BIOGEN INC. |
10% Owner | Sell | 23,660 |
| 2021-12-23 | BIOGEN INC. |
10% Owner | Sell | 81,187 |
| 2021-12-27 | BIOGEN INC. |
10% Owner | Sell | 600 |
| 2021-12-28 | BIOGEN INC. |
10% Owner | Sell | 2,764 |
| 2022-02-12 | Schott Robert J. |
SVP, Head of Development | Tax | 5,463 |
| 2022-02-25 | Carey Robert |
Director | Award | 25,000 |
| 2022-02-25 | Fontenot Jason D. |
SVP, Chief Scientific Officer | Tax | 6,248 |
| 2022-02-25 | Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY | Tax | 1,566 |
| 2022-02-25 | Zakrzewski Joseph S |
Director | Award | 25,000 |
| 2022-02-25 | McClung David Mark |
EVP, Chief Operating Officer | Award | 59,400 |
| 2022-02-25 | Duraibabu Prathyusha |
Director | Award | 41,000 |
| 2022-02-25 | Ramelmeier Rolf Andrew |
EVP, Technical Operations | Award | 145,800 |
| 2022-02-25 | Macrae Sandy |
Director, PRESIDENT, CEO AND DIRECTOR | Award | 224,000 |
| 2022-02-25 | Macrae Sandy |
Director, PRESIDENT, CEO AND DIRECTOR | Tax | 49,890 |
| 2022-02-25 | Meyers James R |
Director | Award | 12,500 |
| 2022-02-25 | Smith Karen L. |
EVP, Chief Medical Officer | Award | 12,500 |
| 2022-02-25 | Schott Robert J. |
SVP, Head of Development | Award | 110,700 |
| 2022-02-25 | Ramelmeier Rolf Andrew |
EVP, Technical Operations | Award | 54,000 |
| 2022-02-25 | Duraibabu Prathyusha |
Director | Award | 110,700 |
| 2022-02-25 | Hillan Kenneth J. |
Director | Award | 25,000 |
| 2022-02-25 | McClung David Mark |
EVP, Chief Operating Officer | Award | 160,380 |
| 2022-02-25 | Ramelmeier Rolf Andrew |
EVP, Technical Operations | Tax | 12,388 |
| 2022-02-25 | McClung David Mark |
EVP, Chief Operating Officer | Tax | 4,610 |
| 2022-02-25 | Ramasastry Saira |
Director | Award | 25,000 |
| 2022-02-25 | PARKER H STEWART |
Director | Award | 12,500 |
Showing 101–150 of 436 transactions